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Abstract: Near-infrared dyes can be used as theranostic agents in cancer management, based
on their optical imaging and localized hyperthermia capabilities. However, their clinical translatability is limited by issues such as photobleaching, short circulation times, and nonspecific
biodistribution. Nanoconjugate formulations of cyanine dyes, such as IR820, may be able to
overcome some of these limitations. We covalently conjugated IR820 with 6 kDa polyethylene
glycol (PEG)-diamine to create a nanoconjugate (IRPDcov) with potential for in vivo applications. The conjugation process resulted in nearly spherical, uniformly distributed nanoparticles
of approximately 150 nm diameter and zeta potential -0.4±0.3 mV. The IRPDcov formulation
retained the ability to fluoresce and to cause hyperthermia-mediated cell-growth inhibition, with
enhanced internalization and significantly enhanced cytotoxic hyperthermia effects in cancer cells
compared with free dye. Additionally, IRPDcov demonstrated a significantly longer (P0.05)
plasma half-life, elimination half-life, and area under the curve (AUC) value compared with
IR820, indicating larger overall exposure to the theranostic agent in mice. The IRPDcov conjugate
had different organ localization than did free IR820, with potential reduced accumulation in the
kidneys and significantly lower (P0.05) accumulation in the lungs. Some potential advantages
of IR820-PEG-diamine nanoconjugates may include passive targeting of tumor tissue through
the enhanced permeability and retention effect, prolonged circulation times resulting in increased
windows for combined diagnosis and therapy, and further opportunities for functionalization,
targeting, and customization. The conjugation of PEG-diamine with a near-infrared dye provides a multifunctional delivery vector whose localization can be monitored with noninvasive
techniques and that may also serve for guided hyperthermia cancer treatments.
Keywords: fluorescent imaging, hyperthermia, image-guided therapy, nanotechnology
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The development of multifunctional agents for cancer management is a rapidly growing
field that can result in improved diagnosis and therapy for patients with cancer. The
use of multifunctional modalities that possess diagnostic and therapeutic properties,
referred to as theranostics, enables a combined approach to detection and treatment.1–6
One of the main challenges in combining early diagnosis and therapy is that imaging
and therapeutic probes are typically different in terms of selectivity and biodistribution.7
This complicates the process of monitoring responses to treatment, which in turn
creates difficulties in planning, timing, and assessing the success of interventions.
In a multifunctional agent, the ability to follow the distribution of an agent in vivo,
thanks to its imaging capabilities, enables the localization of the target site, which can
be followed by the activation of the therapeutic modality once the agent has reached
its desired destination. This ensures that therapy occurs at the desired site and at the
appropriate time. Multifunctional formulations can also allow real-time monitoring
of the effect of therapy. By combining both therapy and diagnostic capabilities into
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a single platform, theranostic agents provide clinicians with
a multipurpose tool that can be used to detect, image, treat,
and monitor therapeutic response over time.8 As a result,
clinicians can implement therapy at an earlier stage, as well
as achieve increased safety, sensitivity, and efficacy in heterogeneously natured diseases, such as cancer.8,9
Near-infrared (NIR) dyes can be used as theranostic
agents in cancer management, based on their optical imaging
and localized hyperthermia capabilities; however, they have
important limitations in their applicability for theranostic use,
especially in terms of photobleaching, in vivo instability,
and nonspecific biodistribution.10 Our group has studied the
properties of the cyanine dye IR820, and we provided the
first detailed report of its potential for use in theranostics.11
IR820 is structurally similar to indocyanine green (ICG),
which is a clinically approved cyanine dye, but IR820 has
improved in vitro and in vivo stability. Our prior work has
shown that IR820 is a feasible agent in experimental models
of imaging and hyperthermia, and could be an alternative to
ICG when greater stability, longer image collection times,
or more predictable peak locations are desirable.11 Our group
has also developed and characterized several formulations
for combined chemotherapy, imaging, and hyperthermia,
using chemotherapy agents and NIR dyes.12,13
Several recent studies have applied IR820 dye or conjugates of the dye for in vivo applications. Prajapati et al
used IR820 as a blood pool contrast agent to image tissue
injuries and tumors in mice.14 Pandey et al conjugated IR820
with a photodynamic therapy drug and studied the resulting conjugate in mice, with IR820 being used exclusively
for its imaging role.15 Masotti et al conjugated IR820 with
polyethylenimine (PEI) for DNA binding applications and
in vivo imaging.16 Thierry et al17 prepared poly(allylamine
hydrochloride)-poly(acrylic acid)-coated magnetic iron oxide
and gold nanoparticles, which were loaded with cisplatin as
well as with a conjugate of IR820 and PEI, following the
work done by Masotti et al. None of these studies exploited
the inherent ability of IR820 to be used as a dual imaging
and hyperthermia agent. Our group has developed several
IR820-based theranostic formulations, including IR820loaded polymeric nanoparticles as well as IR820-chitosan
conjugates and ionic IR820 polyethylene glycol (PEG)diamine conjugates, and we have characterized the imaging
and hyperthermia capabilities of these agents.18–21
Based on its optical and hyperthermia-generation properties, IR820 is a promising theranostic agent; however, clinical
translation of NIR-imaging and hyperthermia approaches in
cancer must overcome the challenges presented by free-dye
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formulations, in terms of plasma circulation times and nonspecific biodistribution. The creation of nanoformulations of
IR820 provides some opportunities to improve in vivo stability and target delivery. Nanosize therapeutic and diagnostic
agents can be tailored to a specific application by manipulating their size, shape, surface characteristics, and other
physiochemical properties. They are also less susceptible to
reticuloendothelial system clearance and have better penetration into tissues and cells than do larger size agents,22,23
and passive targeting to tumor sites can be achieved by the
enhanced permeability and retention effect (EPR).24
We chose to conjugate IR820 with PEG because the
presence of PEG in nanoformulations can reduce immune
interactions and result in improved plasma circulation times.25
Longer exposure to the theranostic agent provides a wider
window of opportunity for diagnosis and therapy, and allows
more flexibility in terms of the timing of one with respect to
the other, as needed for a specific application. Additionally,
PEG can be used as a linker to conjugate other moieties and
impart new functionality, such as specific targeting. Covalent
attachment of PEG does not affect side chain properties in
solution so that formulations covalently bound to PEG will
maintain their functionality.26,27
Our group previously reported the formulation of
ionic IR820-PEG-diamine nanoconjugates, which showed
enhanced cellular internalization in cancer cells for imaging purposes compared with the free dye, and significantly
enhanced hyperthermia-mediated cytotoxicity in MES-SA
and MES-SA/Dx5 (Dx5) cancer cells compared with the
hyperthermia achieved using free dye.21 Although promising,
the ionic nanoconjugates only improved on the stability of the
free dye for up to 4 hours in a phosphate buffer. Given that
IR820 retained its ability to generate heat and fluoresce when
interacting in close proximity with PEG as part of an ionic
formulation, we hypothesized that creating a covalent formulation could further improve on the stability of the lattice and,
in turn, result in nanosize conjugates that might be used in
in vivo applications with improved pharmacokinetic profiles
compared with the free dye, while retaining its theranostic
properties. Thus, we prepared and characterized covalent
conjugates of IR820 and PEG-diamine (IRPDcov).
The size and surface morphology of these nanoconjugates were characterized by transmission electron microscopy (TEM), conjugation was confirmed by proton nuclear
magnetic resonance (1H NMR), and the optical properties
in solution were studied using spectrofluorometry and spectrophotometry. We explored possible applications through
in vitro experiments with three different human cancer cell
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lines (MES-SA, Dx5, and SKOV-3) to investigate the feasibility of using the nanoconjugates as imaging agents and
to determine whether this formulation retained the ability
to induce hyperthermic cell killing. Finally, we performed
pharmacokinetics and biodistribution studies in mice to
compare IRPDcov, free IR820 and ICG, and to determine
whether the nanoconjugates show an advantage with respect
to free-cyanine dyes in terms of in vivo applications.

A mixture of PEG-diamine (6 kDa, 30 mg/5 mL) and IR820
(9.4 mg/5 mL) in aprotic methanol was refluxed for 4 hours in
the presence of distilled triethylamine (2 eq). The molar ratio
was 1:2, PEG-diamine:IR820, based on available functional
groups (two amines in PEG-diamine and one chloro group
in IR820). The reaction scheme (Figure 1) involves covalent attachment of the amine group in PEG-diamine to the
cyclohexene in IR820 at the chloro-substituted position via
nucleophilic substitution, with displacement of the chlorine
atom and production of triethylamine hydrochloride. After
the reaction progressed to completion, the sample was concentrated, and the residue was dissolved in 5 mL of water,
followed by dialysis against water, using a molecular weight
cutoff (MWCO) 3.5 kDa, for 24 hours. The nanoconjugates

Methods
Nanoconjugate preparation
PEG-diamine (6 kDa), IR820, methanol, dimethylsulfoxide
(DMSO) (99.9% reagent grade), and triethylamine were
purchased from Sigma-Aldrich Corp., (St Louis, MO, USA).
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Figure 1 Reaction scheme and formulation of covalent IR820-PEG-diamine nanoconjugate (IRPDcov).
Abbreviations: IRPDcov, covalent conjugates of IR820 and PEG-diamine; PEG, polyethylene glycol; TEA, triethylamine.
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were freeze-dried (FreeZone Plus 6 Liter Cascade Console
Freeze Dry System; Labconco Corp., Kansas City, MO,
USA) for 24 hours and stored in powder form at 4°C for
further use. The choice of 6 kDa PEG-diamine was based on
the criteria of resulting nanoparticle size, nanoparticle charge,
reduced steric hindrance, and conservation of fluorescent
and hyperthermic properties of the dye once combined with
PEG-diamine.

Nanoconjugate characterization
Freeze-dried IRPDcov particles were resuspended in distilled
water and later dropped onto a copper grid and dried at room
temperature. The surface morphology of the samples was
observed under a TEM (CM 200; FEI, Hillsboro, Oregon,
USA) operated at 200-keV pulse at different resolutions. The
nanoconjugate zeta potential was measured using a Zetasizer
Nano ZS (Malvern Instruments, Malvern, UK) employing
a nominal 5 mW helium–neon (He Ne) laser operating at
633 nm wavelength. The scattered light was detected at a
135° angle. The refractive index (1.33) and the viscosity
(0.89 cP) of ultrapure water at 25°C were used for measurements. For 1H NMR measurements, samples of IR820,
PEG-diamine, and IRPDcov were dissolved in deuterated
methanol. The 1H NMR spectra were recorded on a 400 MHz
Avance Bruker NMR spectrometer (Bruker Corp., Billerica,
MA, USA), using 240 scans. Acquired data was processed
and analyzed using MestReNova software. Chemical shifts
were reported in parts per million (ppm) for 1H NMR on
a δ scale based on the deuterated methanol solvent peak
(δ =3.31 ppm) as an internal standard.

Dye content determination
The IR820 content in the freeze-dried nanoconjugates
was determined by dissolving a known amount of sample
in DMSO, sonicating to ensure complete dissolution, and
performing serial dilutions in the fluorescence linear range.
Sample fluorescence was measured at peak emission after
785 nm excitation, with a FluoroLog®-3 spectrofluorometer
(Horiba Jobin Yvon, Kyoto, Japan), under constant operating conditions. The amount of IR820 in the samples was
determined from a calibration curve of free IR820 in DMSO
after 785 nm excitation, using blank subtraction.

Characterization of absorption
properties
We prepared samples of IR820, PEG-diamine, and IRPDcov
in deionized water at 100 μg/mL concentration and performed serial dilutions in the linear range. The concentration
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of IRPDcov was normalized to dye content. Sample absorption, from 200 to 900 nm, was measured with a Cary UV
Spectrophotometer (Agilent Technologies, Santa Clara,
CA, USA).

Fluorescence spectra and fluorescence
stability studies
We prepared samples of IR820 and IRPDcov in phosphatebuffered saline (PBS) buffer, at concentrations in the linear
range, and measured their baseline fluorescence emission
profile after 785 nm excitation. Sample emission fluorescence
was measured from 795 nm up to 850 nm, at 1 nm intervals,
using the FluoroLog-3 spectrofluorometer. Different aliquots
from the same sample batch were kept in the refrigerator and
measured, following the same procedures, for up to 72 hours
after preparation. The emission peak value was used to
determine changes from baseline, and the percent remaining
fluorescence intensity was calculated. Statistical significance
was determined by comparing percent remaining intensities,
using a t-test (α =0.05).

Cytotoxicity with and without
hyperthermia
The cytotoxicity of four different treatments (IR820, IRPDcov, IR820 plus laser, and IRPDcov plus laser) was studied
in cancer cell lines MES-SA, Dx5, and SKOV-3, using the
sulforhodamine B (SRB) colorimetric assay. Cells were
seeded onto 96-well plates at an approximate density of
6.2×104 cells/cm2 and incubated overnight for attachment to
the well, followed by treatment with free IR820 or IRPDcov.
The SRB assay was performed 24 hours posttreatment to
determine net cell growth. Tested IR820 concentrations
ranged from 0 to 5 µM, where IR820 concentration equal
to zero meant that only DPBS and no drug was added to the
wells (control group). Tested IRPDcov concentrations were
normalized to IR820 content in the particles so that the treatments were equivalent to tested concentrations of free dye.
In order to test the effect of hyperthermia, some of the
cells were incubated for 1 hour with one of the following
treatments: 5 μM IR820, IRPDcov at concentrations equivalent to 5 μM of IR-820, or only cell medium. These cells were
then exposed to 808 nm laser illumination for 3 minutes,
and the SRB assay was performed 24 hours postlaser treatment. Temperature was measured with a thermocouple, and
experimental wells were separated from each other by at
least one empty well in all directions to avoid cross-effects.
Net growth values were calculated by normalizing the data
from each treatment to the growth of the control cells, which
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were not exposed to IR820, IRPDcov, or laser. Statistical
significance (P0.05) was identified by one-way analysis
of variance (ANOVA) for the difference among groups at
the same treatment concentration, and between each group
and the control group.

Cellular imaging
Lysine-coated coverslips were placed in each well of a 24-well
plate. MES-SA, Dx5, and SKOV-3 cells were seeded on the
coverslips at a density of 5.2×104 cells/cm2, 5.2×104 cells/cm2,
and 2.6×104 cells/cm2, respectively, in McCoy’s 5A medium
supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin, and were grown overnight for attachment. The next
day, the cell medium was removed and replaced with 5 μM
IR820 or equivalent free-dye content of IRPDcov. Cells were
incubated in the dark at 37°C for 4 hours and then washed
three times with Dulbecco’s phosphate-buffered saline
(DPBS). Then the cells were fixed with 4% formaldehyde for
15 minutes at 37°C, followed by washing three times with
DPBS. The coverslips were then removed and mounted on
glass microslides with antifade reagent/mounting medium
mixture. The cells were then examined by fluorescence
microscopy (Olympus IX81; Olympus Corporation, Tokyo,
Japan) with a 60× water-merged objective. The fluorescence
was imaged at λex (775 nm), λem (845 nm), with an exposure
time of 4,000 ms, which is well below the 20,000 ms threshold
for autofluorescence for this wavelength. A charge-coupled
device (CCD) camera was used to capture the signals, and
the images were software-merged with pseudo color. The
fluorescence microscope settings were kept the same throughout the experiment. The acquired fluorescence images were
processed by MATLAB® (The MathWorks Inc., Natick, MA,
USA) to calculate the image ratio (R). First, the intensity
of each pixel was background-subtracted, and a region of
interest was defined as being composed of any pixels with
above-background intensity values (defined as an intensity of
at least two out of a 255 scale after background subtraction).
The ratio R was then determined by normalizing the total pixel
intensity of this region of interest to its total area.

Animal study design
All animal protocols were approved by the Florida International University Institutional Animal Care and Use
Committee. Thirty-six healthy ND4 Swiss Webster outbred
mice, weighing between 25 and 30 grams, were purchased
from Harlan Laboratories (Indianapolis, IN, USA), housed
under a 12-hour light/dark cycle and fed ad libitum. Mice
were randomly assigned to one of twelve groups (n=3) based
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on optical agent (ICG, IR820, or IRPDcov) and time point
of data collection after injection (15 minutes, 30 minutes,
60 minutes, and 24 hours). Solutions for injection were prepared based on a 0.24 mg/kg dose of free dye,28 which in the
case of IRPDcov, was based on conjugate dye content.
For time groups in the range of minutes, mice were
injected with intraperitoneal (IP) pentobarbital (40 mg/kg for
initial anesthesia during imaging, and an additional 60 mg/kg
for euthanasia after imaging was completed). The animals
were shaved, placed supine on the imaging setup described
in the “In vivo imaging techniques” section below, injected
through the tail vein with their assigned agent, and imaged. At
the predetermined time point, a blood sample was obtained,
under anesthesia, by heart puncture into the ventricle, and the
animal was then euthanized by removal of the heart.
For mice in the 24-hour groups, each animal was anesthetized with 40 mg/kg of IP pentobarbital, injected with the
assigned agent, and imaged. These mice were then returned to
their cage alive until the 24-hour time point. After 24 hours,
they were again anesthetized with pentobarbital, and imaging
was performed under the same operating conditions. After
imaging, a blood sample was obtained by heart puncture
while under anesthesia, and the animals were euthanized by
removal of the heart. Organs were carefully harvested for
imaging and subsequent homogenization and dye extraction
in DMSO.

In vivo imaging techniques
An imaging system consisting of a Sanyo DL 7140-201S
laser (80 mW, 785 nm) and a Retiga 1300 CCD camera was
used. The entire setup was covered by BK5 blackout material.
The power at the imaging plane ranged from 0.1–0.5 mW.
An image of the mouse was obtained under white light illumination to determine the position of the target and to focus
the camera before dye injection. Then, the laser was turned
on, and another image was taken prior to dye injection, to
establish background. Laser current was set to 60 mA. After
the white and background images were obtained, the dye
solution was injected through the tail vein. The camera started
recording immediately before the injection, and 10-second
exposure images of the abdomen were recorded in series,
using QCapture Pro software, for at least 10 minutes. The
same procedures were followed for 24-hour imaging, except
that a still picture was taken rather than serial images.

Plasma and organ sample processing
Plasma and organ sample processing followed the procedures described by other researchers who have performed
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biodistribution studies of NIR dyes and related compounds.29,30
In the case of blood samples, immediately after collection,
the samples were centrifuged two times for 3 minutes at
12,000 rpm, to extract plasma. Plasma samples were then
incubated in DMSO (1:50 [plasma:DMSO]) in glass vials
covered with aluminum foil for 30 minutes and centrifuged
again. The resulting supernatant was used to perform spectrofluorometric measurements of dye concentration in plasma,
using a previously created calibration curve of IR820 or ICG
in DMSO at 785 nm excitation.
For organ samples in the 24-hour groups, organs were
carefully dissected and placed in black-coated Petri dishes
for imaging. Fluorescent organs were then cut into small
pieces using a scalpel, placed in preweighed glass vials,
and homogenized. Then, 5 mL of DMSO was added for dye
extraction. Samples were incubated in DMSO for 4 hours
and centrifuged at 9,000 rpm for 15 minutes. The supernatant was used to perform spectrofluorometric measurements of dye content, using a previously created calibration
curve of IR820 or ICG in DMSO at 785 nm excitation.
To report the data, organ dye content was normalized to
organ mass.

model. The resulting biexponential fit equations were used
to determine the half-lives of distribution and elimination,
the area under the pharmacokinetic curve (AUC), the mean
plasma residence time, and the clearance rate. The mean
residence time in plasma, tp, is the average time spent by
the agent of interest in plasma, and is given, in its simplest
expression, by:

Pharmacokinetic analysis of plasma data

Results and discussion
Characterization of IRPDcov

Dye concentration in plasma obtained from spectrofluorometer measurements was averaged for each group, and
the average concentration for each time point was entered
into MATLAB. The initial concentration (concentration at
injection) for an average 25 g mouse was estimated to be
approximately 4 µg dye/mL in plasma. Using the Curve
Fitting Tool in MATLAB, average data points at 0, 15, 30,
60 minutes, and 24 hours were fit to biexponential curves
via a least squares algorithm to represent a two-compartment

0.5 µm

Mean plasma
Area under curve
= tp =

residence time
Initial concentration

(1)

The total body clearance rate (ie, volume of agent cleared
from the body per unit time) is given by:
Total body clearance rate =

Dose

Area under curve

(2)

Based on the preceding calculations, we compared the
IRPDcov, IR820, and ICG pharmacokinetic parameters,
using one-way ANOVA (P0.05) followed by Bonferroni
post hoc test.

IRPDcov size and morphology were characterized using
TEM, which showed nearly spherical, uniformly distributed nanoconjugates of approximately 150 nm diameter
(Figure 2). The zeta potential of IRPDcov was -0.4±0.3 mV
due to charge neutralization during formulation. The
nanoconjugates are soluble in aqueous solution, and PEGmediated steric repulsion assists in preventing the formation
of aggregates.

50 nm

Figure 2 TEM images of IRPDcov.
Abbreviations: IRPDcov, covalent conjugates of IR820 and PEG-diamine; PEG, polyethylene glycol; TEM, transmission electron microscopy.
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Particle yield was 74% for a 6kDa PEG-diamine formulation. Samples of IRPDcov in deuterated methanol were also
analyzed by 1H NMR, which confirmed conjugate formation.
The conjugate 1H NMR spectrum contained peaks contributed both from IR820 and PEG-diamine, which suggested
that we had indeed prepared the conjugate. Any unreacted
IR820 would have been removed during the dialysis process,
so the presence of aromatic peaks (in the region between
7 and 9 ppm) indicated that both IR820 and PEG-diamine
were present in the conjugated structure. Additionally, the
spectrum of the conjugate showed an upfield proton shift in
the 7.5–8.5 ppm area compared with the spectrum of free
IR820. This is likely explained by the fact that conjugation
replaces the electron-withdrawing chlorine group in IR820
with an electron-releasing amine group from PEG-diamine,
and indicates that the covalent linkage between IR820 and
PEG-diamine was successful. IRPDcov fluorescent dye
content was determined by spectrofluorometry to be approximately 0.113 mg IR820/mg IRPDcov.

PEG-diamine and IR820 were chosen based on molar ratios
used in the formulation of the nanocomplexes, and IRPDcov
concentration was chosen to approximately match the concentration of the IR820 solution, given the previously estimated
dye content (0.113 mg IR820/mg IRPDcov). IRPDcov displayed a bathochromic main absorption peak shift compared
with IR820 (IRPDcov λmax =702 nm, IR820 λmax =688 nm) as
well as a shift in the secondary absorption peak (located at
836 nm for IRPDcov versus 815 nm for IR820). These shifts
can be attributed to the formation of an extended π system by
the conjugation process. There was also an overall broadening
of the spectral profile. Increased absorption and scattering
within the environment of the nanoconjugate may explain
the spectral observations. There were no peaks above 0.01
AU between 200 and 900 nm for PEG-diamine at 24 μg/mL.
The free-dye spectrum showed a maximum peak at 688 nm,
with almost the same absorption intensity as the IRPDcov
solution, confirming our dye content determination.

Absorbance studies

Fluorescence properties of IRPDcov
and fluorescence stability studies

The ultraviolet (UV)-visible spectra of IR820, PEG-diamine,
and IRPDcov are shown in Figure 3. Concentrations of

A representative fluorescence emission spectrum of IRPDcov
after 785 nm excitation is shown in Figure 4, along with the

1.0
IR820 6.25 µg/mL
IRPDcov 6.25 µg/mL dye content
PEG-diamine 24 µg/mL
0.8
702 nm
688 nm
0.6

AU

836 nm
0.4

0.2

815 nm

0.0
200

400

600

800

1,000

Wavelength (nm)
Figure 3 Absorption spectra of IR820 (solid black), IRPDcov (dashed black), and PEG-diamine (gray) in deionized water.
Abbreviations: IRPDcov, covalent conjugates of IR820 and PEG-diamine; PEG, polyethylene glycol; AU, absorbance units.
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50,000
IR820, 0.625 µg/mL
IRPDcov, 0.625 µg/mL dye content

Fluorescence units

40,000

30,000

20,000

10,000

0
780

800

820

840

860

880

Wavelength (nm)
Figure 4 Fluorescence spectra of IR820 and IRPDcov in phosphate-buffered saline.
Abbreviations: IRPDcov, covalent conjugates of IR820 and PEG-diamine; PEG, polyethylene glycol.

corresponding profile for IR820 at comparable dye content.
After 785 nm excitation, the peak emission for IRPDcov was
located at 822 nm, with fluorescence intensity 6% smaller
than IR820. The slight reduction in fluorescence intensity
may have been due to increased scattering within the structure or to secondary self-absorption due to the presence of
the 836 nm absorption peak. IRPDcov and IR820 solutions
in buffer were measured up to 72 hours after preparation, to
determine the percent remaining fluorescent intensity compared with baseline. Samples were kept at 4°C, in the dark.
The decrease in fluorescence from baseline after 72 hours was
significantly lower for IRPDcov (39.9% decrease) compared
with IR820 (80% decrease) (P0.05). This indicates that
covalent conjugation provides significant stabilization to
the dye, likely as a result of increased rigidity of the IR820
molecule from its incorporation into the nanoconjugate lattice, which would reduce intermolecular IR820 aggregation.
PEG-mediated steric hindrance may also have played a role
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in preventing aggregation of IR820 molecules and the subsequent degradation process. The enhanced preservation of
fluorescence properties also indicates that the conjugate was
stable as formulated for at least 72 hours, based on the large
differences in fluorescence observed between the conjugate
and free-dye samples after that time period.

Cellular imaging
Figure 5 shows fluorescence microscopy images of Dx5,
SKOV-3, and MES-SA cell lines after 4 hours incubation
at 5 μM concentration of IR820 and IRPDcov at equivalent
dye content. This concentration was chosen based on our
previous cellular studies with IR820. In all three cell lines,
intense fluorescence was observed inside the cells after
4-hour incubation with IR820 or IRPDcov, indicating that
both the free dye and the nanoconjugates were capable of
entering the cells. However, the images taken after IRPDcov
incubation showed higher normalized intensity ratios than
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Figure 5 Cellular imaging of Dx5 (A and D), MES-SA (B and E), and SKOV-3 cells (C and F) after a 4-hour incubation with 5 μM dye content of IR820 (top) or IRPDcov
(bottom); 60×, exposure time 4,000 ms, compared against the pixel intensities scaled from 0 to 255.
Abbreviations: IRPDcov, covalent conjugates of IR820 and PEG-diamine; PEG, polyethylene glycol.

did those taken after incubation with equivalent concentrations of IR820, especially in Dx5. Normalized intensity
ratios were 1.8 times larger for IRPDcov than for IR820 in
Dx5, 1.4 times larger in MES-SA, and 1.2 times larger in
SKOV-3. PEG can enhance cell membrane interaction and
increase cell internalization, by osmoelastic coupling and
formation of PEG-induced fusion vesicles.31,32 In the case
of IRPDcov, this may be one of the contributing factors to
enhanced internalization.

Cytotoxicity and hyperthermia studies
When excited with 808 nm light, IR820 spontaneously
releases a significant amount of energy in the form of heat.
In response to photon excitation, electrons in the IR820
molecule transition to different energy levels, and the subsequent process of relaxation results in heat dissipation. We
tested IRPDcov to determine whether the dye in nanoconjugate form was still able to generate heat upon exposure to
an 808 nm NIR laser. At a laser fluence rate of 8 W/cm2, a
solution of 0.038 mg/mL IRPDcov (containing 5 μM IR820)
caused an increase in temperature from 37°C to 42.2°C
after 3 minutes of exposure, demonstrating that covalent
binding of IR820 did not interfere with its heat generation
properties. This temperature is in the moderate hyperthermia
range (41°C–43°C), which can cause significant tumor cell
growth inhibition but does not greatly affect healthy cells.
It has been reported that cancer cells have mechanisms that
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inhibit oxidative metabolism that are specifically activated by
temperatures in this range.33–36 We also tested PEG-diamine
by itself, which did not result in significant changes in temperature after 3-minute laser exposure compared with wells
containing medium only. Therefore, the IR820 component
of the nanoconjugates was responsible for hyperthermia
generation.
SKOV-3, Dx5, and MES-SA cells were chosen to study
the cytotoxic effect of IR820 and IRPDcov on tumor cells,
with and without hyperthermia. Figure 6 shows net cell
growth following incubation with IR820 or IRPDcov, with or
without exposure to laser, for SKOV-3, Dx5, and MES-SA.
All groups were normalized to the control group not exposed
to dye or laser. From our previous studies, we determined
that laser exposure by itself or PEG-diamine by itself did
not cause any significant effect on cell growth for any of
the three cell lines.21
Without laser, IRPDcov demonstrates toxicity comparable to the free dye. There was no significant toxicity in
SKOV-3 or Dx5 compared with the control group, which
was not exposed to IRPDcov or IR820, and there was a
slight growth inhibition in MES-SA cells for either treatment, consistent with our previous reports for IR820 and
IR820 conjugates.11,21 There was no significant difference in
net cell growth between the IR820 group and the IRPDcov
group without laser exposure for any cell line, indicating that
IRPDcov can be safely used up to at least 5 μM.
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Figure 6 Cytotoxicity of IRPDcov or IR820 in cancer cell lines, with or without hyperthermia treatment at 5 μM dye concentration, n=3 experiments, 4 wells/experiment.
Notes: All groups are normalized to the control group not exposed to dye or laser. There was no significant effect of laser exposure per se without IRPDcov or IR820, and
there was no significant effect of PEG-diamine with or without exposure to laser. *Significant difference (P0.05) versus nonlaser group; **significant difference (P0.05)
between laser groups.
Abbreviations: IRPDcov, covalent conjugates of IR820 and PEG-diamine; PEG, polyethylene glycol.

When exposed to laser, cell growth was significantly
inhibited in all three cell lines by both IR820 and IRPDcov.
In MES-SA and Dx5 cell lines, exposure to IRPDcov with
hyperthermia resulted in significantly higher cytotoxicity
(P0.05) compared with IR820. In the case of MES-SA,
IRPDcov plus laser resulted in cell killing, whereas IR820
plus laser caused only cell growth inhibition. In SKOV-3
cells, IRPDcov with hyperthermia produced higher cytotoxicity than did free dye but not enough to reach statistical
significance. Based on the cell imaging results displayed in
Figure 5, there may have been a larger degree of internalization for IRPDcov than for free dye. Although this is not a
direct measurement of uptake, the results of the image analysis seem to indirectly indicate that there may have been higher
amounts of conjugate than free dye present in the cells. This
would be consistent with the increased cytotoxicity effect of
the hyperthermia treatment that can be observed in Figure 6.
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Enhanced internalization would result in larger accumulation
of the dye inside the cell and an accentuated damaging effect
of temperature increases. This seems to be most apparent in
MES-SA cells, where treatment with IRPDcov plus laser
resulted in a cell-killing effect.
It is interesting to note that the hyperthermia-enhanced
cytotoxic effect versus free dye reached statistical significance in MES-SA and Dx5 cell lines but not in SKOV-3.
Other researchers have reported that SKOV-3 cells have
inherent thermotolerance, which could be related to
their characteristic p53 gene mutation.37 Hyperthermiainduced cytotoxicity is controlled by both p53-dependent
and -independent pathways.38–40 Based on existing knowledge, thermosensitivity and thermotolerance depend on an
array of biological, genetic, and environmental factors so
that a specific cause for SKOV-3 thermotolerance within the
context of our studies cannot be determined.
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Animal and organ imaging
Figure 7 shows representative images obtained from ICG,
IR820, and IRPDcov animals 15 minutes and 24 hours after
injection. These images prove that IRPDcov can be used for
in vivo imaging and that it provides an imaging signal comparable to that of IR820. The signal ratio for ICG at 15 minutes
after injection was higher than that of IR820 or IRPDcov;
however, by 24 hours, the intensity of ICG had dropped
significantly in comparison with the other two agents.
The 24-hour ICG signal also seemed to be located in
the lower abdomen, instead of in the liver region as is the
case for the other two agents. Organ images obtained after
24 hours demonstrate a very different biodistribution for
ICG compared with the other two agents. Figure 8 provides a
qualitative comparison of organ signals for IRPDcov, IR820,
and ICG, and Table 1 summarizes the organ signal intensity
per unit area ratios for each dye.
The information obtained from the ratio data indicates
that the biodistribution of IRPDcov, IR820, and ICG shows
a different pattern between agents 24 hours after intravenous
(IV) injection. Although an ICG signal was still present in
the liver, the ratio was significantly lower (P0.05) than for
IR820 or IRPDcov. The amount of ICG present in the kidneys and the lungs was also significantly smaller (P0.05)
than for the other two agents. In the case of the intestines,
a higher signal was observed for ICG than for IR820 or
IRPDcov; however, the effect did not reach statistical significance, due to the large standard deviation for the ICG

A

D

IRPDcov, 15 minutes

IRPDcov, 24 hours

250

B

measurements in the intestines. We expect that intersubject
variability in intestinal motility rates would affect ICG more
markedly, given that most of the dye is being eliminated via
the gastrointestinal tract at the 24-hour time point.
In the case of IR820, a strong signal was observed in
the liver, kidneys, and lungs, with a small signal in the
intestines. IRPDcov showed a strong signal in the liver,
some signal in the kidneys, and a small signal in lungs
and intestines. Statistical analysis comparing IR820 and
IRPDcov showed that there were no differences in liver or
intestinal image ratios. There was a significant difference
(P0.05) in lung image ratios, with IRPDcov showing a
smaller signal ratio than IR820. This possibly indicates
that the nanoformulation was able to escape detection by
alveolar macrophages, thanks to the presence of PEG,
which reduces binding to serum proteins.41 In the kidneys,
the IRPDcov signal was smaller than that of IR820, but
the difference did not reach statistical significance. There
may be a somewhat smaller degree of elimination of
IRPDcov through the kidneys, which would be consistent
with the expectation that the larger size of the conjugate
compared with the free dye would result in decreased renal
clearance (based on a low molecular size cutoff for renal
excretion),42 as well as the fact that the presence of PEG
could result in reduced reticuloendothelial system uptake.
However, the small number of subjects in our study may
not provide enough sensitivity to detect a significant difference. Another reason for the lack of significance could
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Figure 7 Images taken 15 minutes and 24 hours after IV injection for IRPDcov (A and D), IR820 (B and E), and ICG (C and F) compared against the pixel intensities scaled
from 0 to 255.
Note: Mice were shaved for imaging.
Abbreviations: ICG, indocyanine green; IRPDcov, covalent conjugates of IR820 and PEG-diamine; IV, intravenous; PEG, polyethylene glycol.
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Figure 8 Organ images taken 24 hours after IV injection of IRPDcov, IR820, or ICG compared against the pixel intensities scaled from 0 to 255.
Abbreviations: ICG, indocyanine green; IRPDcov, covalent conjugates of IR820 and PEG-diamine; IV, intravenous; PEG, polyethylene glycol.

be variability in renal elimination rates between subjects.
Additionally, imaging ratios may not be sensitive enough
to detect quantitative differences.
From these images, we can conclude that there are clear
differences in the biodistribution patterns of ICG versus
IRPDcov and IR820, with ICG being more rapidly cleared
from major organs than the other two agents, and primarily localizing in fecal elimination pathways by 24 hours.
The difference in behavior was probably due to a much
faster plasma clearance combined with a high level of ICG
binding to plasma proteins, faster liver clearance, and loss
of signal due to poor ICG stability. IR820 and IRPDcov
provide an advantage in terms of prolonged residence

Table 1 Signal intensity ratios for liver, lungs, kidneys and intestines
collected 24 hours after IV injection of IRPDcov, IR820, or ICG
Image intensity per area, R (1/µm2)
Liver
Lungs**
Kidneys
Intestines

IRPDcov

IR820

ICG

6.35±0.44*
0.64±0.08*
1.34±0.13*
0.65±0.10

6.13±1.44*
2.48±0.47*
2.95±1.88*
1.00±0.45

0.76±0.35
0.18±0.32
0.20±0.34
2.01±1.43

Notes: Values represent average ± SD. *Significant difference (P0.05) with ICG
values for the same organ; **significant difference (P0.05) between IRPDcov and
IR820 values for the same organ.
Abbreviations: ICG, indocyanine green; IRPDcov, covalent conjugates of IR820
and PEG-diamine; IV, intravenous; PEG, polyethylene glycol; SD, standard deviation.
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times, although for both these agents, the timing of imaging
would need to be optimized so that the signal is high in the
target tissue and low in the plasma and nontarget tissue. In
terms of comparing IRPDcov with IR820, our lung images
support the hypothesis of reduced mononuclear phagocyte
system uptake,43 which we can probably owe to the presence of PEG. However, this is not the only possible factor
affecting the biodistribution of these conjugates as size
can also play a significant role in the pharmacokinetics of
nanoformulations and their uptake by body tissues. For
instance, particles of sizes larger than 10 nm are unlikely
to undergo glomerular filtration, and the primary elimination route for particles that are not excreted through the
kidneys is the hepatobiliary system,44 consistent with our
observations.

Organ dye content

Figure 9 shows the average dye content (in µg dye/g tissue) for liver, lungs, kidneys, and intestines 24 hours after
an IV injection of IRPDcov, IR820, or ICG. The data is
consistent with our qualitative observations and quantitative
signal ratios from the optical imaging samples, and provides
increased sensitivity to detect differences. When we compare
the results for ICG with those of IRPDcov and IR820, we see
that organ content was significantly higher in the intestines
and significantly lower in all other organs. For lungs and
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Figure 9 Quantitative organ content 24 hours after IV injection of IRPDcov, IR820, or ICG.
Notes: *Significant difference (P0.05) with ICG values for same organ; **significant difference (P0.05) between IRPDcov and IR820 values for same organ. There was no
detectable signal for ICG in lungs or kidneys after 24 hours.
Abbreviations: ICG, indocyanine green; IRPDcov, covalent conjugates of IR820 and PEG-diamine; IV, intravenous; PEG, polyethylene glycol.

kidneys, ICG sample readings were at background level.
When comparing IRPDcov and IR820, the only significant
difference was a reduced content of IRPDcov in the lungs.
IRPDcov kidney content was lower than that for IR820, but
the difference was not significant. This is consistent with
our observations in the organ imaging studies. The difference between intestinal uptake of ICG, IRPDcov, and IR820
became significant once quantitative organ dye content was
used as a measurement.

Plasma dye concentration
Figure 10 shows the average dye concentration in plasma
(in µg/mL) for IRPDcov, IR820, and ICG at each of the
time points under study. We observed significantly higher
(P0.05) plasma concentrations of IR820 and IRPDcov
compared with ICG for all time points, with plasma values
20 times higher for IRPDcov and 10 times higher for IR820,
at 24 hours. We also found significantly higher (P0.05)
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concentrations of IRPDcov compared with IR820 at the
30-minute, 60-minute, and 24-hour time points, with plasma
concentration of IRPDcov double that of IR820 at the 24-hour
sampling time.
Based on these results, not only were IR820 formulations superior to ICG in terms of plasma concentration
over time, but we also observed a clear advantage of the
IRPDcov conjugate over IR820 after initial distribution.
This validates the theoretical basis for the formulation
of this conjugate, which relied on the possibility that the
presence of PEG could contribute to improved plasma concentration profiles by reducing detection by macrophages
and other circulating agents in plasma. IRPDcov is thus
analogous to other formulations in which the inclusion of
PEG has provided some stealth characteristics in an in vivo
environment.45–49
The recovered percent age of injected dose at 24 hours in
plasma was 3.3% for IRPDcov, 1.7% for IR820, and 0.8%
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Figure 10 Plasma concentrations (µg/mL) of IRPDcov, IR820, and ICG at different time points after IV injection.
Notes: *Significant difference from ICG (P0.05); **significant difference IRPDcov vs IR820 (P0.05).
Abbreviations: ICG, indocyanine green; IRPDcov, covalent conjugates of IR820 and PEG-diamine; IV, intravenous; PEG, polyethylene glycol.

for ICG. If we add these numbers to the percentage values
of the recovered injected doses found in our organ content
studies, we reach an overall percentage of 15.1% for IRPDcov, 17.7% for IR820, and 2.6% for ICG. In the case of ICG,
almost the entire injected dose was lost after 24 hours, which
demonstrates a clear advantage of the IR820 formulations in
terms of injected dose recovery at this time point. Surprisingly, we did not observe a larger percentage dose recovery
for IRPDcov compared with IR820. A possible explanation
may be that the circulating concentration of IRPDcov was
still double that of IR820 at 24 hours. It is also possible that
a considerable amount of the conjugate may yet have been
present in other nonsampled tissues, such as fat, skin, muscle,
bone, or the lymphatic system.
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Pharmacokinetic modeling
Table 2 shows the resulting fitted parameters from a twocompartment pharmacokinetics model of the IRPDcov,
IR820, and ICG data, given the biexponential equation:
C(t) = A × e − at + B × e − bt 

(3)

Our results show that both IR820 and IRPDcov demonstrated significantly longer (P0.05) distribution half-lives,
longer elimination half-lives, larger AUC, longer plasma
residence times, and slower body clearance rates than did ICG.
Although distribution happened quite fast for all agents, the
ICG distribution half-life was approximately 3.06 minutes,
whereas the value for IR820 was 13.4 minutes and for
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Table 2 Pharmacokinetic parameters from two-compartment analysis of dye data in mice
IRPDcov
Model equation based
on plasma data
R2
Distribution half-life, h
Elimination half-life, h
AUC, (µg-h)/mL
Mean residence time in plasma, h
Total body clearance rate, mL/h

IR820

C(t) = 3.66×e

-1.91t

+ 0.32×e

-0.020t

0.995
0.364±0.006†,††
35.46±0.56†,††
7.98±0.13†,††
1.99±0.03†,††
0.75±0.01†,††

ICG

C(t) = 3.83×e

-3.12t

0.999
0.223±0.003†,††
30.45±0.45†,††
4.38±0.07†,††
1.09±0.02†,††
1.37±0.02†,††

+ 0.1702×e

-0.023t

C(t) = 3.93×e-13.54t + 0.07×e-0.38t
0.999
0.051±0.001
1.85±0.03
0.490±0.007
0.12±0.002
12.25±0.18

Notes: †Significant difference (P0.05) with ICG; ††significant difference (P0.05) IRPDcov vs IR820.
Abbreviations: AUC, area under the time–concentration curve; ICG, indocyanine green; IRPDcov, covalent conjugates of IR820 and PEG-diamine; PEG, polyethylene glycol.

IRPDcov was 21.8 minutes. The distribution half-life value
for ICG is consistent with that previously reported by other
authors, which has ranged from 2 to 4 minutes.50,51 The calculated elimination half-lives for IRPDcov and IR820, which
both exceeded 30 hours, were in stark contrast with that of
ICG, which was 1.85 hours. These values are also well aligned
with some of the conclusions reached by Prajapati et al who
estimated that IR820 should have a clearance half-life close
to that of albumin, which is in the order of 35 hours.14 The
elimination half-life value we obtained for ICG is consistent
with literature data as other authors report an elimination
half-life of over 1 hour at low concentrations.50
Both the distribution and the elimination phases showed
improved profiles for IR820 formulations compared with
ICG, in terms of providing a wider time window for theranostic action. As far as the AUC, both IRPDcov and IR820
were an order of magnitude larger than ICG, indicating an
increased overall tissue exposure to the theranostic agent.
Additionally, IRPDcov also showed a significant advantage
(P0.05) over IR820 for all the above calculated parameters,
with almost double the AUC and mean plasma residence time
of IR820, and almost half the clearance rate of IR820. The
nanoformulation was present in plasma for longer periods of
time, eliminated more slowly from the body, and the cumulative exposure of body compartments to the conjugate was
larger than for either of the two free dyes. The time that the
IRPDcov was bioavailable was also significantly longer as
the elimination half-life of IRPDcov was 1.16 times longer
than that of IR820 and 19 times longer than that of ICG,
whereas the distribution half-life of IRPDcov was 1.6 times
longer than that of IR820 and seven times longer than that
of ICG.
Given that the enhanced permeability and retention effect
is proportional to the time and amount of agent circulating in
blood,29 we would theoretically expect IRPDcov to result in
a greater amount of dye accumulated and retained in tumors.
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However, further studies in a tumor-bearing model would be
needed to explore this possibility.
Other authors have studied the pharmacokinetics of
nanoformulations, and the general consensus is that nanoformulations may result in improved pharmacokinetic profiles,
in many cases as a result of stabilization of the drug and
reduced metabolism and clearance.42 Still, loss of nanocomplexes from the circulation can occur by binding to serum
proteins in the process known as surface opsonization, which
subsequently causes recognition and removal by circulating
phagocytes or macrophages.47,52 In the case of PEGylated
formulations, steric hindrance reduces the degree of protein
binding, resulting in prolonged circulation times and giving PEGylated formulations an improved pharmacokinetic
profile compared with their non-PEGylated counterparts.42,52
This seems to be applicable to formulations incorporating
PEG as a conjugated moiety, as was the case of the IRPDcov
conjugate.
Another consideration which is intimately tied to these
profiles is the surface charge of the formulation. Our nanoconjugates were zwitterionic, presenting both positive and
negative charges and an overall zeta potential approaching
neutrality. Other authors have found that for other physical
characteristics being similar, neutral and zwitterionic nanoformulations exhibit prolonged plasma half-lives and reduced
clearance compared with largely positive or largely negative
formulations, which indicates that charge may play a large
role in maximizing circulation time.53
Nanocomplex size also has an effect on circulation time,
with particles around 100 nm diameter demonstrating longer blood circulation profiles than larger or smaller particle
sizes.42 Liu et al studied the effect of size on biodistribution
of liposomes and found that sizes between 100 and 200 nm
were present in circulation for longer times than those
greater than 250 nm or smaller than 50 nm.54 Given that our
nanoconjugates were around 150 nm per TEM measurement,
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it seems that size was also contributing to their prolonged
circulation times.
Our analysis is not without possible limitations. First, the
pharmacokinetic models we used have important assumptions, such as uniform distribution, no absorption, rapid
equilibration before sampling, and no degradation. Uniform
distribution may be an issue as we know that nanoformulations are distributed to tissues depending on pore size, in
a different manner than their free-form counterparts.55,56
In terms of rapid equilibration, others have reported that
equilibration of injected solutions in mice plasma can be
assumed to happen within 2 minutes.57 Since our first sample
was taken at 15 minutes, we can assume that equilibration
had occurred by that time. Regarding the possibility of degradation into other byproducts, other authors have shown
that ICG is mostly excreted in its intact form in bile.29 Our
in vitro studies show that IRPDcov conjugates were very
stable and retained their characteristics for at least 72 hours
in PBS. Based on this, we do not expect degradation to be a
significant concern within the time periods studied in vivo.
However, the in vivo environment cannot be fully mimicked
by in vitro conditions, and some in vivo factors, such as
the presence of plasma proteins, reticuloendothelial system
scavengers, and metabolism in liver or other tissues, may
result in aggregation, degradation, or changes in the structure
of these molecules.
Image-guided therapy using IR820 conjugates shows
promise for clinical translation as it can be coupled with minimally invasive light delivery techniques, such as endoscopic
or orthoscopic approaches. Future work will focus on studying the biodistribution of these conjugates in tumor-bearing
animals in order to determine in vivo tumor uptake, as well
as on the design and optimization of minimally invasive in
vivo methods for combined imaging and hyperthermia, possibly through fiber optic technology.

Conclusion
We successfully prepared nanocomplexes of IR820 and
PEG-diamine (IRPDcov) and investigated cellular uptake
and cytotoxicity in cancer cell lines MES-SA, SKOV-3,
and Dx5. The IRPDcov formulation can potentially provide
an advantage over the use of free agents by significantly
enhancing the stability of the NIR dye, increasing cell internalization, allowing simultaneous colocalization of imaging
and therapy, and accentuating the cytotoxic effect of hyperthermia. IRPDcov can be used for in vitro optical imaging
of cancer cells as well as in vivo imaging. Biodistribution
and pharmacokinetic studies of IRPDcov, IR820, and ICG
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in healthy mice show that IRPDcov is a feasible alternative
to IR820 for in vivo imaging and that it demonstrates an
improved pharmacokinetic profile over the free-dye form
as well as over the commonly used NIR dye ICG. IRPDcov
demonstrated significantly longer distribution and elimination half-live, longer mean plasma residence time, larger
overall exposure as indicated by AUC, and slower clearance
rate compared with either IR820 or ICG. The conjugate has
different organ localization than free IR820, with potential
reduced accumulation in the kidneys and significantly lower
(P0.05) accumulation in the lungs. The nanosize nature of
our conjugate, as well as surface and charge characteristics
provided by the presence of PEG, is likely to be responsible
for these differences. The use of IRPDcov conjugates could
provide wider in vivo availability windows for theranostic
applications. Future research will include studies in tumorbearing animals, in order to explore the passive targeting
ability of this formulation as well as to investigate the optimal
dosage that will provide effective therapeutic hyperthermia
and imaging in vivo.
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